US3485825A - Conessine derivatives - Google Patents
Conessine derivatives Download PDFInfo
- Publication number
- US3485825A US3485825A US791805*A US3485825DA US3485825A US 3485825 A US3485825 A US 3485825A US 3485825D A US3485825D A US 3485825DA US 3485825 A US3485825 A US 3485825A
- Authority
- US
- United States
- Prior art keywords
- conessine
- compounds
- bis
- bromide
- dimethylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0042—Nitrogen only
Definitions
- Type I comprises substances with depolarizing properties, such as succinylcholine.
- Cholinesterase inhibitors cannot antagonize their activity.
- the effect of succinylcholine is prolonged on the other hand by cholinesterase inhibition. Its breakdown normally takes place in the plasma under the influence of pseudocholinesterase.
- Products of type II are competitive antagonists of acetylcholine.
- This type includes, inter alia, d-tubocurarine and gallamine. Their activity on the contrary can be antagonized by cholinesterase inhibitors.
- Type III comprises non-competitively acting compounds, such as dioxahexadecanium bromide.
- cholinesterase inhibitors are not antagonistically active.
- Products of type IV inhibit the synthesis of acetylcholine, e.g., the hemicholinia. Cholinesterase inhibitors do have an antagonizing influence. Substances of type IV, however, can readily be distinguished from those of type II, inter alia through the difference in the rapidity with which the block sets in.
- decamethonium which has properties of types I and III.
- a peripherally acting muscular relaxing agent has to meet, inter alia, the following requirements.
- the block should rapidly be complete. If the effect does not rapidly disappear spontaneously, an antagonist should be available, in this case, a cholinesterase inhibitor. If possible, there should be an ample margin between the dose which just paralyzes the respiratory muscles and the smallest dose required to paralyze the other striated muscles completely. Finally, any objectionable side actions, such as muscular pains and an undesirable fall in blood pressure, should be absent.
- An object of the present invention is the obtention of a quaternary ammonium derivative of a compound of the formula having double bonds in the positions selected from the group consisting of the 5,6-position and the 4,5- and 6,7- positions; wherein R R and R are alkyl having from 1 to 5 carbon atoms; and R and R are members selected from the group consisting of two hydrogens, one a-hydroxyl and one hydrogen, one ,B-hydroxyl and one hydrogen; with the proviso that when said double bonds are in the 4,5- and 6,7-positions, R is one hydrogen; said quaternary ammonium derivative being selected from the group consisting of mono-quaternary compounds, bisquaternary compounds and strong mineral acid addition salts of mono-quaternary compounds; said quaternary ammonium derivative being derived from esters of strong mineral acids with an alcohol selected from the group consisting of lower alkanol, lower alkenol, phenyl-loweralkanol and cyclo
- the compound defined above are all type II muscular relaxing agents. They are, therefore, competitive antagonists of acetylcholine and their activity can be antagonized with cholinesterase inhibitors.
- the motor nerve end plate inhibition sets in very rapidly and the rate of its spontaneous disappearance varies, dependent upon the substituents. The latter is of particular importance, for thus, the anaesthetist can make his choice for each individual case from a series of compositions with a very brief to a prolonged effect. Moreover, he can, if necessary, rapidly eliminate the effect by administering an antagonist. Finally, the margin between the dose which paralyzes the respiratory muscles and the dose which paralyzes the other muscles is relatively wide, While an influence on the blood pressure is completely or substantially absent.
- compositions of special importance are 11a-hydroxy 3,6-dimethylamino-n -conenine-bis-ethiodide, which has no undesirable influence on the blood pressure at dosages up to 5 times the therapeutic dosage and has an effect which sets in rapidly, while the rapidity with which the inhibition disappears is relatively low; 3fi-dimethylamino- A -conenine-mono-ethiodide, which causes an increase in blood pressure of short duration, the blocking effect setting in very rapidly and disappearing very rapidly; and 3B dimethylamino A conadienine mono 3N- ethoiodide which differs from the other compounds of the invention in that it has no undesirable influence the blood pressure and the electrocardiogram (ECG) at dosages up to times the therapeutic dosage, and hence is a very safe drug. At such dosages the compound causes only a slight and short-lasting rise of the blood pressure, but no dangerous lowering of the blood pressure occurs in this wide range of dosages.
- ECG electrocardiogram
- the invention relates to the above-defined compounds with the exception of bis-metho-compounds of conessine.
- the last-mentioned compounds are excluded, as Heilbronn, Dictionary of Organic Compounds, vol. 2, p. 730, states the bis-metho-iodide and the bis-metho-sulfate of conessine, but without mention of any pharmacological activity.
- the bis-metho-compounds of conessine show a smaller margin between the dose which paralyzes the respiratory muscles and the dose which paralyzes the other muscles, than the other compounds of the invention.
- the invention further relates to a process for preparing the above-defined compound.
- the compounds are prepared by reacting the corresponding non-quaternized compounds with a quaternizing agent.
- Suitable quaternizing agents are the familiar esters of aliphatic and araliphatic alcohols derived from strong acids. Aliphatic and araliphatic esters of sulfuric acid, hydrohalogenic acids, such as hydrochloric acid, hydrobromic acid, or hydroiodic acid, may be mentioned as examples, in particular, the iodides and bromides. As alcohols, of particular importance are the lower alkanols, lower alkenols, phenyl-lower-alkanols and cycloalkyllower-alkanols.
- the quaternizing esters are preferably ethyl iodide, methyl iodide, ethyl bromide, methyl bromide, methyl sulfate, allyl bromide, benzyl bromide, cyclohexylmethyl bromide, etc.
- the quaternizing reaction is carried out in the conventional way, for instance, by boiling the starting material, such as conessine or a conessine derivative, in a suitable solvent, such as acetonitrile, alcohols, mixtures of alcohols and water, benzene, or acetone with an alkyl or aralkyl halide.
- a suitable solvent such as acetonitrile, alcohols, mixtures of alcohols and water, benzene, or acetone with an alkyl or aralkyl halide.
- the mono-quaternary compounds are preferably obtained by boiling in anhydrous or 90% ethanol. In most cases compounds with a quaternized 3-dialkylamino group are thus obtained. A quaternization of the nitrogen of the pyrrolidine ring alone, however, is not precluded.
- the invention also relates to pharmaceutical compositions containing the compounds according to the inven tion, as well as to processes for preparing such compositions.
- the pharmaceutical compositions can be prepared in a usual way.
- the compounds in question are preferably dissolved in a physiological salt solution, may or may not be placed in particular doses in ampoules under an inert gas, and may subsequently be sterilized in the conventional way.
- the compositions can be used for human as Well as veterinary practice.
- the corresponding bis-methoiodide is prepared in an analogous manner. It melts at 296 to 297 C.
- Conessine bis-ethiodide 5 gm. of conessine and 40 ml. of ethyl iodide (freshly distilled) are boiled in ml. of acetonitrile with reflux cooling.
- Conessine monoethiodide hydroiodide 5 gm. of conessine and 12 ml. of ethyl iodide (freshly distilled) are boiled in m1. of anhydrous ethanol with reflux cooling.
- the product is filtered off and washed with acetone.
- the crude product is recrystallized several times more from methanolacetone. Yield 4.15 gm.; melting point :263 to 266 C.
- Conessine bis-benzyl bromide 10 gm. of conessine and ml. of benzyl bromide are boiled in 100 ml. of acetonitrile for 3 /2 hours with reflux cooling, after Which the mixture is evaporated under reduced pressure. The residue is dissolved in dilute sulfuric acid (1 N) and the solution is shaken outwith heptane to remove the excess of benzyl bromide. The solution is subsequently basified and extracted with methyl isobutyl ketone, non-converted conessine and any conessine monobenzyl bromide that may have formed being extracted.
- the aqueous layer is evaporated under reduced pressure and the residue (consisting of Na SO and conessine bis-benzyl bromide) is stirred with anhydrous ethanol.
- the suspension thus obtained is filtered through a short aluminum oxide column.
- the column is Washed with anhydrous ethanol until no more conessine bisbenzyl bromide is present in the filtrate.
- the precipitate thus formed is subsequently filtered 01f and washed with acetonitrile.
- This precipitate consists substantially of conessine dihydrobromide.
- the corresponding 7a-hydroxy compound is prepared in an analogous manner (melting point approximately 230 C.).
- I.R.-spectrum in chloroform: 2788, 1709, 1634, and 1600 cmi- N.M.R.-spectrum (in CDCl 0.98, 1.04 (doublet), 1.50 (triplet), 1.92 (doublet), 2.23, 3.07 (doublet), 3.30, 3.75 (quadruplet), 4.6 (multiplet), 5.55, 5.9, and 6.1 (AB-spectrum) p.p.m.
- the liquids used had been prepared as follows:
- the water was boiled and saturated with nitrogen gas during cooling.
- EXAMPLE XII having double bonds in the positions selected from the group consisting of the 5,6-position and the 4,5- and 6,7- positions; wherein R R and R are alkyl having from 1 to 5 carbon atoms; and R and R are members selected from the group consisting of two hydrogens, one whydroxyl and one hydrogen, and one B-hydroxyl and one hydrogen, with the proviso that when said double bonds are in the 4,5- and 6,7-positions, R is one hydrogen; said quaternary ammonium derivative being selected from the group consisting of mono-quaternary compounds, bisquaternary compounds and strong mineral acid addition salts of mono-quaternary compounds; said quaternary ammonium derivative being derived from esters of strong mineral acids with an alcohol selected from the group consisting of lower alkanol, lower alkenol, phenyl-loweralkanol and cycloalkyl-loWer-alkanol, with the proviso that when the double bond is in the 5,6-position,
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
nited States Patent 3,485,825 CONESSINE DERIVATIVES Arthur Friedrich Marx, Delft, and Jacob Wieriks,
Pijnacker, Netherlands, assignors to Koninklijke, N ederlandsche Gist 8; Spiritusfahriek N.V., Delft, Netherlands, a corporation of the Netherlands No Drawing. Continuation-in-part of application Ser. No. 529,202, Feb. 23, 1966. This application Jan. 16, I969, Ser. No. 791,805 Claims priority, application Netherlands, Feb. 26, 1965, 6502483 Int. Cl. C07c 173/00 US. Cl. 260239.5 Claims ABSTRACT OF THE DISCLOSURE Certain monoand bis-quaternary ammonium derivatives of conessine and its related compounds having a 3/3- di-alkylamino substituent useful as muscular relaxing agents acting as competitive antagonists of acetylcholine, as well as therapeutic compositions containing them.
PRIOR APPLICATION This application is a continuation in part of our copending US. patent application Ser. No. 529,202, filed Feb. 23, 1966, now abandoned.
THE PRIOR ART For the induction of muscular relaxation, e.g. during surgical operations, a number of products are already known, which can be classified into four different types on the basis of their properties.
Type I comprises substances with depolarizing properties, such as succinylcholine. Cholinesterase inhibitors cannot antagonize their activity. The effect of succinylcholine is prolonged on the other hand by cholinesterase inhibition. Its breakdown normally takes place in the plasma under the influence of pseudocholinesterase.
Products of type II are competitive antagonists of acetylcholine. This type includes, inter alia, d-tubocurarine and gallamine. Their activity on the contrary can be antagonized by cholinesterase inhibitors.
Type III comprises non-competitively acting compounds, such as dioxahexadecanium bromide. Here again cholinesterase inhibitors are not antagonistically active.
Products of type IV inhibit the synthesis of acetylcholine, e.g., the hemicholinia. Cholinesterase inhibitors do have an antagonizing influence. Substances of type IV, however, can readily be distinguished from those of type II, inter alia through the difference in the rapidity with which the block sets in.
Finally, there are substances which have mixed properties, such as decamethonium, which has properties of types I and III.
A peripherally acting muscular relaxing agent has to meet, inter alia, the following requirements. The block should rapidly be complete. If the effect does not rapidly disappear spontaneously, an antagonist should be available, in this case, a cholinesterase inhibitor. If possible, there should be an ample margin between the dose which just paralyzes the respiratory muscles and the smallest dose required to paralyze the other striated muscles completely. Finally, any objectionable side actions, such as muscular pains and an undesirable fall in blood pressure, should be absent.
None of the existing muscular relaxing agents meets all these requirements to the full.
OBJECTS OF THE INVENTION An object of the present invention is the obtention of a quaternary ammonium derivative of a compound of the formula having double bonds in the positions selected from the group consisting of the 5,6-position and the 4,5- and 6,7- positions; wherein R R and R are alkyl having from 1 to 5 carbon atoms; and R and R are members selected from the group consisting of two hydrogens, one a-hydroxyl and one hydrogen, one ,B-hydroxyl and one hydrogen; with the proviso that when said double bonds are in the 4,5- and 6,7-positions, R is one hydrogen; said quaternary ammonium derivative being selected from the group consisting of mono-quaternary compounds, bisquaternary compounds and strong mineral acid addition salts of mono-quaternary compounds; said quaternary ammonium derivative being derived from esters of strong mineral acids with an alcohol selected from the group consisting of lower alkanol, lower alkenol, phenyl-loweralkanol and cycloalkyl-lower-alkanol, with the proviso that when the doube bond is in the 5,6position, R R R :CH and R R H said alkanol has from 2 to 6 carbon atoms.
This and further objects of the present invention will become more apparent as the description thereof proceeds.
DESCRIPTION OF THE INVENTION Now is was found that monoand bis-quaternary ammonium derivatives of compound having the formula which contain a double bond in the position 5, 6 or in the positions 4, 5 and 6,7, and in which R R and R each stand for an alkyl group with no more than 5 carbon atoms, while R and R each stand for two hydrogen atoms or one hydrogen atom and one aor B-hydroxyl group, as well as acid addition salts of the mono-quaternary ammonium compounds, are eminently suitable for use as muscular relaxing agents.
The compound defined above are all type II muscular relaxing agents. They are, therefore, competitive antagonists of acetylcholine and their activity can be antagonized with cholinesterase inhibitors. The motor nerve end plate inhibition sets in very rapidly and the rate of its spontaneous disappearance varies, dependent upon the substituents. The latter is of particular importance, for thus, the anaesthetist can make his choice for each individual case from a series of compositions with a very brief to a prolonged effect. Moreover, he can, if necessary, rapidly eliminate the effect by administering an antagonist. Finally, the margin between the dose which paralyzes the respiratory muscles and the dose which paralyzes the other muscles is relatively wide, While an influence on the blood pressure is completely or substantially absent.
Compositions of special importance are 11a-hydroxy 3,6-dimethylamino-n -conenine-bis-ethiodide, which has no undesirable influence on the blood pressure at dosages up to 5 times the therapeutic dosage and has an effect which sets in rapidly, while the rapidity with which the inhibition disappears is relatively low; 3fi-dimethylamino- A -conenine-mono-ethiodide, which causes an increase in blood pressure of short duration, the blocking effect setting in very rapidly and disappearing very rapidly; and 3B dimethylamino A conadienine mono 3N- ethoiodide which differs from the other compounds of the invention in that it has no undesirable influence the blood pressure and the electrocardiogram (ECG) at dosages up to times the therapeutic dosage, and hence is a very safe drug. At such dosages the compound causes only a slight and short-lasting rise of the blood pressure, but no dangerous lowering of the blood pressure occurs in this wide range of dosages.
The invention relates to the above-defined compounds with the exception of bis-metho-compounds of conessine. The last-mentioned compounds are excluded, as Heilbronn, Dictionary of Organic Compounds, vol. 2, p. 730, states the bis-metho-iodide and the bis-metho-sulfate of conessine, but without mention of any pharmacological activity. The bis-metho-compounds of conessine show a smaller margin between the dose which paralyzes the respiratory muscles and the dose which paralyzes the other muscles, than the other compounds of the invention.
The invention further relates to a process for preparing the above-defined compound. The compounds are prepared by reacting the corresponding non-quaternized compounds with a quaternizing agent.
Suitable quaternizing agents are the familiar esters of aliphatic and araliphatic alcohols derived from strong acids. Aliphatic and araliphatic esters of sulfuric acid, hydrohalogenic acids, such as hydrochloric acid, hydrobromic acid, or hydroiodic acid, may be mentioned as examples, in particular, the iodides and bromides. As alcohols, of particular importance are the lower alkanols, lower alkenols, phenyl-lower-alkanols and cycloalkyllower-alkanols. The quaternizing esters are preferably ethyl iodide, methyl iodide, ethyl bromide, methyl bromide, methyl sulfate, allyl bromide, benzyl bromide, cyclohexylmethyl bromide, etc.
The quaternizing reaction is carried out in the conventional way, for instance, by boiling the starting material, such as conessine or a conessine derivative, in a suitable solvent, such as acetonitrile, alcohols, mixtures of alcohols and water, benzene, or acetone with an alkyl or aralkyl halide.
By boiling in acetonitrile with a sufiicient quantity of quaternizing agent, it is primarily the bis-quaternary am monium compounds which are obtained, while in the other solvents mentioned it is generally mixtures of the monoand the bis-quaternary compounds which are formed.
The mono-quaternary compounds are preferably obtained by boiling in anhydrous or 90% ethanol. In most cases compounds with a quaternized 3-dialkylamino group are thus obtained. A quaternization of the nitrogen of the pyrrolidine ring alone, however, is not precluded.
The invention also relates to pharmaceutical compositions containing the compounds according to the inven tion, as well as to processes for preparing such compositions. The pharmaceutical compositions can be prepared in a usual way. The compounds in question are preferably dissolved in a physiological salt solution, may or may not be placed in particular doses in ampoules under an inert gas, and may subsequently be sterilized in the conventional way. The compositions can be used for human as Well as veterinary practice.
EXAMPLE I 3B-dimethylamino-11a-hydroxy-A -conenine-bis-ethiodide 1.5 gm. of 3/3-dimethylamino-l1u-hydroxy-A -conenine and 15 ml. of ethyl iodide (freshly distilled) are boiled in 40 ml. of acetonitrile for 12 hours with reflux cooling.
The mixture is then cooled to room temperature, the crystallized product being sucked off, washed with acetonitrile, and dried under reduced pressure at 45 C. Yield==2.2 gm.; melting point=292.5203.5 C. After recrystallization from methanol the melting point is 292 to 293 C.
Analysis.Calculated: C, 49.12%; H, 7.31%; l. 37.13%. Found: C, 49.34%, 49.21%; H, 7.13%, 7.10%: I, 37.02%, 37.12%.
Infrared spectra (KBr): No absorptions for N-CH or N+H.
The corresponding bis-methoiodide is prepared in an analogous manner. It melts at 296 to 297 C.
EXAMPLE II Conessine bis-ethiodide 5 gm. of conessine and 40 ml. of ethyl iodide (freshly distilled) are boiled in ml. of acetonitrile with reflux cooling.
After 6 /2 hours the mixture is cooled to room temperature and the product is isolated and purified in the Way described in Example 1. Yield 5.4 gm.; melting point=288.5 to 289 C.
Analysis.C H N I Calculated: C, 50.30%; N. 4.19%; H; 7.49%; I, 38.02%. Found: C, 50.25%, 50.05%; N, 4.20%, 4.24%; H, 7.41%, 7.48%; I, 38.20%. 38.12%.
Infrared spectra (KBr): No absorption for NCH or N+H.
EXAMPLE III Conessine monoethiodide hydroiodide 5 gm. of conessine and 12 ml. of ethyl iodide (freshly distilled) are boiled in m1. of anhydrous ethanol with reflux cooling.
After three hours boiling the reaction mixture is cooled to room temperature and then evaporated under reduced pressure. The residue is dissolved in 30 ml. of 50% methanol, basified with 2 ml. of 11 N sodium hydroxide solution, and shaken out with methyl isobutyl ketone. The extract is evaporated under reduced pressure. The remaining crude product (5.9 gm.) is dissolved in methanol and the solution is filtered. To the filtrate is added 1.2 ml. of hydroiodic acid (45%), after which the mixture is concentrated under reduced pressure to about 10 ml. The crystallized product is filtered off and washed with cold methanol. The product is then recrystallized once more from methanol. Yield 5.3 gm.; melting point: 294.5 to 295.5 C.
Analysis.C H N I.I-II. Calculated: C, 48.75%; H. 7.19%; N, 4.38%; I, 39.69%. Found: C, 48.64%. 48.74%; H, 7.21%, 7.23%; N, 4.16%, 4.11%; I, 39.46%. 39.57%.
For LR. and N.M.R. analyses, 1 gm. of the hydroiodide is converted into conessine mono-ethiodide (melting point=272 to 273 C.).
AnaLysis.-C H N I. Calculated: C, 60.94%; H, 8.79%; N, 5.48%; I, 24.80%. Found: C, 60.85%, 60.83%; H, 8.73%, 8.75%; N, 5.40%, 5.48%; I, 24.88%. 24.81%.
LR. (KBr): 2775 cm. (bl-CH N.M.R. (CDCl 6:2.22 ppm. (3H from NCH EXAMPLE IV Conessine bis-allyl bromide gm. of conessine and ml. of allyl bromide are boiled in 100 ml. of acetonitrile for 45 minutes with reflux cooling. The mixture is then cooled to 0 C., after Which the crystallized product is sucked off and Washed with cold acetonitrile.
The crude product is recrystallized several times from methanol-acetone. Yield 8.3 gm.; melting point=270 to 273 C.
Arralysz's.-C H N Br Calculated: C, 60.20%; H, 8.36%; N, 4.68%; Br, 26.76%. Found: C, 59.90%, 59.96%; H, 8.41%, 8.44%; N, 4 .61%, 4.66%; Br, 26.59%, 26.52%.
IR. (KBr): 3080 cm. (CH from C=CH 3014 cm.- (CH from C C H), 1665 cm.- (C=C), 1649 cm.- (C=C), no absorption for N--CH N.M.R. (D 0): 6:2.92 p.p.m. (3H; N+CH 6:3.0 p.p.m. (6H; N+(CH 5=3.94.0 p.p.m. (4H; multiplet; N+CHg), 5=5.55.7 p.p.m. (3H; C=C H), 6:5.8 p.p.m. (4H; C=CH EXAMPLE V Conessine mono-allyl bromide hydrobromide 10 gm. of conessine and 4 ml. of allyl bromide are boiled in 150 ml. of 96% ethanol for 4 hours With reflux cooling. The mixture is then concentrated under reduced pressure to about 50 ml. To this quantity are added 50 ml. of water and 2.5 ml. of 11 N sodium hydroxide solution, and the mixture is extracted With methyl isobutyl ketone. The extract thus obtained is evaporated under reduced pressure and the residue is dissolved in a small quantity of methanol. To this solution hydrobromic acid (37%) is added until the pH is 3, and then acetone upon which the product is crystallizing.
The product is filtered off and washed with acetone. The crude product is recrystallized several times more from methanolacetone. Yield 4.15 gm.; melting point :263 to 266 C.
Analysis.C H N Br-HBr. Calculated: C, 57.71%; H, 8.24%; N, 5.02%; Br, 28.67%. Found: C, 57.45%, 57.84%; H, 8.31%, 8.22%; N, 4.80%, 4.94%; Br, 28.72%, 28.30%.
For LR. and N.M.R. analyses 300 mg. of the HBr salt is converted into conessine mono-allyl bromide.
LR. (KBr): 3070 cm.- (CH from C H 3020 cm. (CH from C=C H), 2878 cm? (NCH 1665 cm." (C C), 1640 cm. (C C).
EXAMPLE VI Conessine bis-benzyl bromide 10 gm. of conessine and ml. of benzyl bromide are boiled in 100 ml. of acetonitrile for 3 /2 hours with reflux cooling, after Which the mixture is evaporated under reduced pressure. The residue is dissolved in dilute sulfuric acid (1 N) and the solution is shaken outwith heptane to remove the excess of benzyl bromide. The solution is subsequently basified and extracted with methyl isobutyl ketone, non-converted conessine and any conessine monobenzyl bromide that may have formed being extracted. The aqueous layer is evaporated under reduced pressure and the residue (consisting of Na SO and conessine bis-benzyl bromide) is stirred with anhydrous ethanol. The suspension thus obtained is filtered through a short aluminum oxide column. The column is Washed with anhydrous ethanol until no more conessine bisbenzyl bromide is present in the filtrate. The filtrate is evaporated under reduced pressure and the residue is recrystallized several times from methanol-methyl isobutyl ketone. Yield 8.4 gm.; melting point=235 to 237 C.
Analysis.C H N Br Calculated: C, 65.33%; H, 7.74%; N, 4.01%; Br, 22.92%. Found: C, 65.36%, 65.15%; H, 7.69%, 7.79%; N, 3.93%, 4.02%; Br, 22.71%, 22.85%.
LR. (KBr): No absorption for NCH 1700 cm.- 1620 cm. 1580 cm. 1450 cm.- (phenyl absorption), 745 cm. and 705 cm.- (mono-substituted benzene).
N.M.R. (D 0): F299 p.p.m. (9H; N+(CH and N+CH 6:7.54 p.p.m., 6:7.60 p.p.m.
1 10H two phenyl groups.
EXAMPLE VII Conessine monobenzyl bromide hydrobromide 10 gm. of conessine and 6 ml. of benzyl bromide are boiled in 150 ml. of 96% ethanol With reflux cooling.
After 6 /2 hours the reaction is broken off and the mixture is evaporated under reduced pressure. The residue is dissolved in 1 N sulfuric acid and the solution is shaken out With heptane to remove the excess of benzyl bromide. The acid solution is subsequently basified and extracted With methyl isobutyl ketone. The organic extract is evaporated under reduced pressure. The residue is dissolved in methanol; hydrobromic acid (37%) is added until the pH is 3, and then ether until the solution becomes turbid. The product is then allowed to crystallize at 0 C. The crystallized product is sucked off and Washed With ether. Yield 8.6 gm. After another recrystallization from methanol-ether the melting point is 258- 260 C.
Analysis.-C H N Br-HBr. Calculated: C, 61.18%; H, 7.89%; N, 4.61%; Br, 26.32%. Found: C, 60.84%, 60.92%; H, 8.04%, 8.05%; N, 4.66%, 4.57%; Br, 25.95%, 26.14%.
IR. (KBr): 3060 cmf 3030 cm. and 3015 cm.- (CH from phenyl), 2620 cmf 2549 cm. and 2520 cm." (N 'H), 1583 cm. and 1450 cm." (C C from phenyl), 745 cm. and 703 cm. (mono-substituted benzene).
N.M.R. (D 0): p286 p.p.m. (3H; N+CH 6:302 p.p.m. (6H; N+(CH F560 p.p.m. (1H; C C H), 0 758 p.p.m. (5H; phenyl).
EXAMPLE VIII Conessine monocyclohexyl methobromide 5 gm. of conessine and 80 ml. of cyclohexylmethyl bromide are boiled in ml. of acetonitrile and 20 ml. of anhydrous ethanol with reflux cooling.
After 48 hours the reaction is broken off and the mixture is kept for several hours at 0 C.
The precipitate thus formed is subsequently filtered 01f and washed with acetonitrile. This precipitate consists substantially of conessine dihydrobromide.
Water is added to the filtrate, and after acidification to pH 3 the mixture is extracted several times with heptane.
The aqueous layer is subsequently made alkaline With sodium hydroxide solution to pH 10 and shaken out With methyl isobutyl ketone. The extract is evaporated under reduced pressure and the residue is purified with the aid of an aluminum oxide column.
Yield of conessine monocyclohexyl methobromide 1.3 gm.; melting point 265 to 267 C. After several recrystallizations from methanol-ether the compound melts at 270.5 to 273 C.
Analysis.C H N Br. Calculated: C, 69.79%, H, 9.94%; N, 5.25%; Br, 15.00%. Found: C, 69.69%, 69.75%; H, 9.63%, 9.62%; N, 5.12%, 507%; Br 15.48%, 15.35%.
I.R. (KBr): 2775 cm? (NCH N.M.R. (C D SO): 6 2.10 p.p.m. (3H; NCH 6:3.04 p.p.m. (6H; N+(CH 7 EXAMPLE IX 3 fl-dimethylamino-7 B-hydroxy-M-conenine bis-methiodide 400 mg. of 3,B-dimethylamino-7-hydroxy-A -conenine and 2 ml. of methyl iodide (freshly distilled) are boiled in 20 ml. of methanol with reflux cooling.
After 2 hours the reaction is broken ofi? and the mixture is evaporated under reduced pressure. The residue is dissolved in water, basified with amonia, and shaken out with methyl isobutyl ketone. The aqueous layer is subsequently evaporated under reduced pressure and the residue is recrystallized several times from methanolmethyl isobutyl ketone.
Yield of 3B-dimethylamino-7,8-hydroXy-A -conenine bismethiodide 320 mg. Melting point:294 to 296 C.
Analysis.C H N OI Calculated: C, 47.56%; H, 7.01%; N, 4.26%; I, 38.71%. Found: C, 47.40%, 47.33%; H, 7.10%, 7.14%; N, 4.15%, 4.20%; -I, 38.53%, 38.44%.
IR. (KBr): No absorption for N-CH or N H.
The corresponding 7a-hydroxy compound is prepared in an analogous manner (melting point approximately 230 C.).
EXAMPLE X 3fl-dimethylamino-A -conadienine bis-methiodide 400 mg. of 3B-dimethylamino-A -conadienine (J Chem. Soc., 1957, 4957) are reacted in the way described in Example IX with 2 ml. of methyl iodide. The product obtained is 474 mg. of 3[3-dimethylamino-A -conadienine bis-methiodide with a melting point of 214.5 to 215 C.
Analysis.-C H N I Calculated: C, H, 6.90%; N, 4.39%; I, 39.81%. Found: C, 48.63%, 48.71%; H, 7.02%, 7.09%; N, 4.28%, 4.23%; I, 38.91%, 39.03%.
LR. (KBr): No absorption for NCH or N H.
EXAMPLE XI 3/3-dimethylamino-A -conadienine 3N-ethoiodide of the formula A solution of 110 g. of 3B-dimethylamino-A -conadienine in 2.75 liters of hexane and 0.55 liters of ethyliodide was refluxed with stirring under a nitrogen atmosphere on a water bath maintained at 75 C. As far as possible the reaction was carried out in the dark. After a reaction time of 22 hours, thin-layer chromatography (A1 0 CH Cl /CH OH, 25:1, vol/vol.) showed that about 80% of the starting material had been converted into the desired compound, and very little of the bisquaternary derivative has been formed.
As far as possible, the isolation and purification steps were carried out in a nitrogen atmosphere. The reaction mixture was cooled and the crystals formed were filtered ofi with suction, and washed with hexane. The crystal mass was dissolved in 1 liter of CH Cl and 3 liters of water. The mixture was shaken and the organic layer was separated. The aqueous layer was extracted three times with 0.5 liters of CH Cl The combined methylene chloride extracts were washed four times with 100 ml. of water. The extract was concentrated in vacuo to a volume of about 1 liter. Subsequently, concentration was continued under slow addition of acetone to the mixture, until a thick crystal suspension was obtained. This suspension and 546 respectively; [a] (c.=0.5% in chloroform).
I.R.-spectrum (in chloroform): 2788, 1709, 1634, and 1600 cmi- N.M.R.-spectrum (in CDCl 0.98, 1.04 (doublet), 1.50 (triplet), 1.92 (doublet), 2.23, 3.07 (doublet), 3.30, 3.75 (quadruplet), 4.6 (multiplet), 5.55, 5.9, and 6.1 (AB-spectrum) p.p.m.
Analysis.-C H N I; molecular weight=510. Calculated: C, 61.18%; H, 8.43%; -N, 5.49%; I, 24.90%. Found: C, 60.61%; H, 8.50%; N, 5.40%; I, 25.49%.
The liquids used had been prepared as follows:
Hexane and ethyl iodide were filtered through A1 0 and saturated with nitrogen gas.
CH Cl and acetone were also saturated with nitrogen gas.
The water was boiled and saturated with nitrogen gas during cooling.
EXAMPLE XII having double bonds in the positions selected from the group consisting of the 5,6-position and the 4,5- and 6,7- positions; wherein R R and R are alkyl having from 1 to 5 carbon atoms; and R and R are members selected from the group consisting of two hydrogens, one whydroxyl and one hydrogen, and one B-hydroxyl and one hydrogen, with the proviso that when said double bonds are in the 4,5- and 6,7-positions, R is one hydrogen; said quaternary ammonium derivative being selected from the group consisting of mono-quaternary compounds, bisquaternary compounds and strong mineral acid addition salts of mono-quaternary compounds; said quaternary ammonium derivative being derived from esters of strong mineral acids with an alcohol selected from the group consisting of lower alkanol, lower alkenol, phenyl-loweralkanol and cycloalkyl-loWer-alkanol, with the proviso that when the double bond is in the 5,6-position,
9 and R :R =H said alkanol has from 2 to 6 carbon atoms.
2. The quaternary derivative of claim 1 wherein said quaternary ammonium derivative is derived from ethyl iodide.
3. 11oz hydroxy -3,B dimethylarnino A conenine- 5 bis-ethiodide.
4. Conessine-rnono-ethiodide-hydroiodide. 5. 3 8-dimethylamino-A -conadienine-3N-ethi0dide.
References Cited UNITED STATES PATENTS 2,912,432 11/1959 Pappo et 211. 2,913,455 11/1959 Pappo.
HENRY A. FRENCH, Primary Examiner US. Cl. X.R. 260-999
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL6502483A NL6502483A (en) | 1965-02-26 | 1965-02-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
US3485825A true US3485825A (en) | 1969-12-23 |
Family
ID=19792503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US791805*A Expired - Lifetime US3485825A (en) | 1965-02-26 | 1969-01-16 | Conessine derivatives |
Country Status (6)
Country | Link |
---|---|
US (1) | US3485825A (en) |
BE (1) | BE676980A (en) |
CH (1) | CH498823A (en) |
FR (1) | FR5242M (en) |
GB (1) | GB1104731A (en) |
NL (2) | NL6502483A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050227953A1 (en) * | 2004-04-07 | 2005-10-13 | Chen Zhao | Azacyclosteroid histamine-3 receptor ligands |
WO2005100377A1 (en) * | 2004-04-07 | 2005-10-27 | Abbott Laboratories | Azacyclosteroid histamine-3 receptor ligands |
US20100040568A1 (en) * | 2008-04-30 | 2010-02-18 | Skinmedica, Inc. | Steroidal compounds as melanogenesis modifiers and uses thereof |
US9295664B2 (en) | 2011-06-06 | 2016-03-29 | University Of Iowa Research Foundation | Methods for lowering blood glucose |
US9856204B2 (en) | 2010-05-20 | 2018-01-02 | University Of Iowa Research Foundation | Methods for inhibiting muscle atrophy |
US11090313B2 (en) | 2010-05-20 | 2021-08-17 | University Of Iowa Research Foundation | Methods for inhibiting muscle atrophy |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL6908367A (en) * | 1969-01-16 | 1970-07-20 | Koninklijke Gist Spiritus |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2912432A (en) * | 1958-11-28 | 1959-11-10 | Searle & Co | 3-oxo and 3-hydroxy derivatives of 18-dimethyl-aminopregn-20-enes and intermediates |
US2913455A (en) * | 1958-05-22 | 1959-11-17 | Searle & Co | 18-dimethylamino steroids and intermediates |
-
0
- NL NL124636D patent/NL124636C/xx active
-
1965
- 1965-02-26 NL NL6502483A patent/NL6502483A/xx unknown
-
1966
- 1966-02-09 GB GB5776/66A patent/GB1104731A/en not_active Expired
- 1966-02-24 BE BE676980D patent/BE676980A/xx unknown
- 1966-02-24 FR FR50997A patent/FR5242M/fr not_active Expired
- 1966-02-25 CH CH278466A patent/CH498823A/en not_active IP Right Cessation
-
1969
- 1969-01-16 US US791805*A patent/US3485825A/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2913455A (en) * | 1958-05-22 | 1959-11-17 | Searle & Co | 18-dimethylamino steroids and intermediates |
US2912432A (en) * | 1958-11-28 | 1959-11-10 | Searle & Co | 3-oxo and 3-hydroxy derivatives of 18-dimethyl-aminopregn-20-enes and intermediates |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050227953A1 (en) * | 2004-04-07 | 2005-10-13 | Chen Zhao | Azacyclosteroid histamine-3 receptor ligands |
WO2005100377A1 (en) * | 2004-04-07 | 2005-10-27 | Abbott Laboratories | Azacyclosteroid histamine-3 receptor ligands |
US7345034B2 (en) | 2004-04-07 | 2008-03-18 | Abbott Laboratories | Azacyclosteroid histamine-3 receptor ligands |
US20080113982A1 (en) * | 2004-04-07 | 2008-05-15 | Chen Zhao | Azacyclosteroid histamine-3 receptor ligands |
US20100040568A1 (en) * | 2008-04-30 | 2010-02-18 | Skinmedica, Inc. | Steroidal compounds as melanogenesis modifiers and uses thereof |
US9856204B2 (en) | 2010-05-20 | 2018-01-02 | University Of Iowa Research Foundation | Methods for inhibiting muscle atrophy |
US11090313B2 (en) | 2010-05-20 | 2021-08-17 | University Of Iowa Research Foundation | Methods for inhibiting muscle atrophy |
US9295664B2 (en) | 2011-06-06 | 2016-03-29 | University Of Iowa Research Foundation | Methods for lowering blood glucose |
US10137136B2 (en) | 2011-06-06 | 2018-11-27 | University Of Iowa Research Foundation | Methods for inhibiting muscle atrophy |
US10668087B2 (en) | 2011-06-06 | 2020-06-02 | University Of Iowa Research Foundation | Methods for inhibiting muscle atrophy |
Also Published As
Publication number | Publication date |
---|---|
NL124636C (en) | |
NL6502483A (en) | 1966-08-29 |
CH498823A (en) | 1970-11-15 |
GB1104731A (en) | 1968-02-28 |
FR5242M (en) | 1967-07-17 |
BE676980A (en) | 1966-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3474101A (en) | Thebaine and oripavine derivatives | |
US3485825A (en) | Conessine derivatives | |
US2824875A (en) | Certificate of correction | |
US4587253A (en) | Bridged pyridine compounds useful as calcium channel blockers and analgesics | |
US2780577A (en) | Inhibiting polymethylene diquaternary curariform activity by alpha-stilbazoline derivatives | |
US2993899A (en) | Acetylenically unsaturated piperazine derivatives | |
US3966936A (en) | Piperazino quinazoline bronchodilators | |
US3852455A (en) | 4-{8 4({60 hydroxybenzyl)piperidino{9 -4-fluorobutyrophenone derivatives as tranquilizers | |
US3936450A (en) | Anti-inflammatory agents and method for their preparation | |
US3272827A (en) | Alpha-phenyl-beta-(2-furyl propionitrile compounds and a process of making same | |
US3192253A (en) | N-substituted methoxyphenoxy-ethylamines | |
US2740788A (en) | J-hydroxy-n-propargyl-morphinanes | |
US3148118A (en) | Analeptically active agents | |
US3070624A (en) | Glycyrrhetinic acid dialkylaminoalkyl esters | |
JPS6140268A (en) | Imidazoline, addition salt, manufacture and medicine | |
US3468891A (en) | Dihydronorthebainone and dihydronororipavinone compounds and corresponding enol lower alkyl ethers | |
US2914532A (en) | Lower alkyl 4-phenyl-1-(3-phenylpropyl) piperidine-4-carboxylates and their preparation | |
US3974285A (en) | 10,11-Furo-derivatives of cyproheptadine | |
US3743735A (en) | Pharmaceutical compositions containing tropanol esters of alpha-phenyl-alpha-cyclopentyl-acetic acid and methods of use | |
US3652559A (en) | Diaminocycloalkanes | |
US2830988A (en) | 2-aryl-2-amino methyl dioxolane-(1,3) compounds and a process of making same | |
US3506670A (en) | 2-hetero-amino-alpha,alpha-diaryl-cycloalkone-methanols and esters thereof | |
US3170933A (en) | 2-(gamma-methoxypropyl-aminomethyl)-1, 4-benzodioxane | |
US2957876A (en) | N-aminopiperidinium salt | |
US3270024A (en) | Heterocyclic amino phenoxyacetic acid amides, acid addition salts, and quaternary ammonium salts thereof |